Pimobendan (BioDeep_00000182434)

   

human metabolite blood metabolite


代谢物信息卡片


4,5-dihydro-6-(2-(4-Methoxyphenyl)-1H-benzimidazole-5-yl)-5-methyl-3(2H)-pyridazinone

化学式: C19H18N4O2 (334.1429688)
中文名称: 匹莫苯丹
谱图信息: 最多检出来源 Homo sapiens(blood) 86.86%

分子结构信息

SMILES: CC1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)OC
InChI: InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)

描述信息

D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors
D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
D020011 - Protective Agents > D002316 - Cardiotonic Agents

同义名列表

11 个代谢物同义名

4,5-dihydro-6-(2-(4-Methoxyphenyl)-1H-benzimidazole-5-yl)-5-methyl-3(2H)-pyridazinone; 6-[2-(4-methoxyphenyl)-1H-1,3-benzodiazol-5-yl]-5-methyl-4,5-dihydropyridazin-3-ol; DL-Pimobendan; Pimobendanum; Pimobendane; Pimobendan; UD-CG 115; UD CG 115; vetmedin; UD-CG115; Acardi



数据库引用编号

11 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Júlia Leão, Valeria Luiza Winck, Cesar Liberato Petzhold, Fabricio Mezzomo Collares, Diego Fontana de Andrade, Ruy Carlos Ruver Beck. Pimobendan controlled release guar gum printlets: Tailoring drug doses for personalised veterinary medicines. International journal of pharmaceutics. 2024 Apr; 655(?):124017. doi: 10.1016/j.ijpharm.2024.124017. [PMID: 38508429]
  • Sarah M Ozawa, David Sanchez-Migallon Guzman, Michelle G Hawkins, Stephanie M Diao, Acacia E Masri, Catherine T Gunther-Harrington, Heather K Knych. Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus). American journal of veterinary research. 2022 Jan; 83(4):356-363. doi: 10.2460/ajvr.21.03.0032. [PMID: 35038306]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Darcy Adin, Kari Kurtz, Clarke Atkins, Mark G Papich, Shelly Vaden. Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease. Journal of veterinary internal medicine. 2020 Jan; 34(1):53-64. doi: 10.1111/jvim.15662. [PMID: 31769114]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Melanie J Hezzell, Chloë L Block, Danielle S Laughlin, Mark A Oyama. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease. Journal of veterinary internal medicine. 2018 Sep; 32(5):1509-1516. doi: 10.1111/jvim.15228. [PMID: 30216549]
  • J N King, C Christinaz, G Strehlau, J Hornfeld. Effect of benazepril and pimobendan on serum angiotensin-converting enzyme activity in dogs. Journal of veterinary pharmacology and therapeutics. 2018 Jun; 41(3):485-489. doi: 10.1111/jvp.12475. [PMID: 29392741]
  • Rina Nabeta, Hironari Osada, Misato Ogawa, Ayana Hasegawa, Miori Kishimoto, Hirotada Murayama, Toshinori Yoshida, Makoto Shibutani, Hiroshi Itoh, Keitaro Ohmori. Clinical and pathological features and outcome of bilateral incidental adrenocortical carcinomas in a dog. The Journal of veterinary medical science. 2017 Sep; 79(9):1489-1493. doi: 10.1292/jvms.17-0153. [PMID: 28781295]
  • M Yata, A J McLachlan, D J R Foster, A S Hanzlicek, N J Beijerink. Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology. 2016 Dec; 18(4):310-325. doi: 10.1016/j.jvc.2016.07.001. [PMID: 27613648]
  • João Brandão, Caryn A Reynolds, Hugues Beaufrère, Jacqueline Serio, Robert V Blair, Lorrie Gaschen, James G Johnson, Fabio Del Piero, Steven A Barker, Javier G Nevarez, Thomas N Tully. Cardiomyopathy in a Harris hawk (Parabuteo unicinctus). Journal of the American Veterinary Medical Association. 2016 Jul; 249(2):221-7. doi: 10.2460/javma.249.2.221. [PMID: 27379599]
  • M Yata, A J McLachlan, D J R Foster, S W Page, N J Beijerink. Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs. Journal of veterinary pharmacology and therapeutics. 2016 Feb; 39(1):45-53. doi: 10.1111/jvp.12243. [PMID: 25997373]
  • E T Bell, J L Devi, S Chiu, P Zahra, T Whittem. The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs. Journal of veterinary pharmacology and therapeutics. 2016 Feb; 39(1):54-61. doi: 10.1111/jvp.12235. [PMID: 25989021]
  • Yuki Otsuki, Yoshinobu Nakamura, Shingo Harada, Yasutaka Yamamoto, Kazuhide Ogino, Kumi Morikawa, Haruaki Ninomiya, Shigeru Miyagawa, Yoshiki Sawa, Ichiro Hisatome, Motonobu Nishimura. Adipose stem cell sheets improved cardiac function in the rat myocardial infarction, but did not alter cardiac contractile responses to β-adrenergic stimulation. Biomedical research (Tokyo, Japan). 2015; 36(1):11-9. doi: 10.2220/biomedres.36.11. [PMID: 25749147]
  • Yamir Reina-Doreste, Joshua A Stern, Bruce W Keene, Sandra P Tou, Clarke E Atkins, Teresa C DeFrancesco, Marisa K Ames, Timothy E Hodge, Kathryn M Meurs. Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. Journal of the American Veterinary Medical Association. 2014 Sep; 245(5):534-9. doi: 10.2460/javma.245.5.534. [PMID: 25148095]
  • David Sanchez-Migallon Guzman, Hugues Beaufrère, Butch KuKanich, Steven A Barker, João Brandão, Joanne Paul-Murphy, Thomas N Tully. Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis). Journal of avian medicine and surgery. 2014 Jun; 28(2):95-101. doi: 10.1647/2012-061. [PMID: 25115037]
  • Hiroaki Kawano, Shuji Arakawa, Osami Satoh, Yuji Matsumoto, Motonobu Hayano, Daisuke Nakatomi, Toshihiko Yamasa, Koji Maemura. Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure. Geriatrics & gerontology international. 2014 Jan; 14(1):109-14. doi: 10.1111/ggi.12067. [PMID: 23581555]
  • Liang Guo, Luke Coyle, Rory M C Abrams, Raymond Kemper, Eric T Chiao, Kyle L Kolaja. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicological sciences : an official journal of the Society of Toxicology. 2013 Dec; 136(2):581-94. doi: 10.1093/toxsci/kft205. [PMID: 24052561]
  • J Häggström, P F Lord, K Höglund, I Ljungvall, O Jöns, C Kvart, K Hansson. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure. Journal of veterinary internal medicine. 2013 Nov; 27(6):1452-62. doi: 10.1111/jvim.12217. [PMID: 24128373]
  • Marisa K Ames, Clarke E Atkins, Andrea C Lantis, Stephen R Werre. Effect of furosemide and high-dosage pimobendan administration on the renin-angiotensin-aldosterone system in dogs. American journal of veterinary research. 2013 Aug; 74(8):1084-90. doi: 10.2460/ajvr.74.8.1084. [PMID: 23879846]
  • Eryn A Shipley, Daniel F Hogan, Nonya N Fiakpui, Aliya N Magee, Henry W Green, Kimberly A Sederquist. In vitro effect of pimobendan on platelet aggregation in dogs. American journal of veterinary research. 2013 Mar; 74(3):403-7. doi: 10.2460/ajvr.74.3.403. [PMID: 23438115]
  • Andrew S Hanzlicek, Ronette Gehring, Butch Kukanich, Kate S Kukanich, Michele Borgarelli, Nicole Smee, Emily E Olson, Marco Margiocco. Pharmacokinetics of oral pimobendan in healthy cats. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology. 2012 Dec; 14(4):489-96. doi: 10.1016/j.jvc.2012.06.002. [PMID: 23116650]
  • Andrea C Lantis, Clarke E Atkins, Teresa C DeFrancesco, Bruce W Keene, Stephen R Werre. Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs. American journal of veterinary research. 2011 Dec; 72(12):1646-51. doi: 10.2460/ajvr.72.12.1646. [PMID: 22126693]
  • M W S Martin, M J Stafford Johnson, G Strehlau, J N King. Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases. The Journal of small animal practice. 2010 Aug; 51(8):428-36. doi: 10.1111/j.1748-5827.2010.00966.x. [PMID: 20670255]
  • M B Sayer, C E Atkins, Y Fujii, A K Adams, T C DeFrancesco, B W Keene. Acute effect of pimobendan and furosemide on the circulating renin-angiotensin-aldosterone system in healthy dogs. Journal of veterinary internal medicine. 2009 Sep; 23(5):1003-6. doi: 10.1111/j.1939-1676.2009.0367.x. [PMID: 19737179]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • M Fusellier, J-C Desfontis, A Le Roux, S Madec, F Gautier, A Thuleau, M Gogny. Effect of short-term treatment with meloxicam and pimobendan on the renal function in healthy beagle dogs. Journal of veterinary pharmacology and therapeutics. 2008 Apr; 31(2):150-5. doi: 10.1111/j.1365-2885.2007.00934.x. [PMID: 18307507]
  • Nobuyuki Kanno, Hiroshi Kuse, Masaya Kawasaki, Akashi Hara, Rui Kano, Yoshihide Sasaki. Effects of pimobendan for mitral valve regurgitation in dogs. The Journal of veterinary medical science. 2007 Apr; 69(4):373-7. doi: 10.1292/jvms.69.373. [PMID: 17485924]
  • Michi Wakaumi, Tsuyoshi Shiga, Miyoko Naganuma, Naoki Matsuda, Shinji Tatami, Hiroshi Kasanuki. Plasma concentration profile of orally administered pimobendan and plasma brain natriuretic peptide level in patients with severe heart failure. Cardiovascular drugs and therapy. 2003 May; 17(3):291-3. doi: 10.1023/a:1026201029821. [PMID: 14669747]
  • T Sasaki, T Kubo, K Komamura, T Nishikimi. Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. Journal of cardiology. 1999 Jun; 33(6):317-25. doi: NULL. [PMID: 10396705]
  • K M Chu, O Y Hu, S M Shieh. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects. Drug metabolism and disposition: the biological fate of chemicals. 1999 Jun; 27(6):701-9. doi: NULL. [PMID: 10348800]
  • P Schneider, J Güttner, A Eckenfels, G Heinzel, H von Nicolai, G Trieb, H Lehmann. Comparative cardiac toxicity of the i.v. administered benzimidazole pyridazinon derivative Pimobendan and its enantiomers in female Beagle dogs. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie. 1997 Aug; 49(3-4):217-24. doi: 10.1016/s0940-2993(97)80013-9. [PMID: 9314056]
  • K M Chu, S M Shieh, O Y Hu. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. Clinical pharmacology and therapeutics. 1995 Jun; 57(6):610-21. doi: 10.1016/0009-9236(95)90223-6. [PMID: 7781260]
  • K M Chu, S M Shieh, O Y Hu. Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese. European journal of clinical pharmacology. 1995; 47(6):537-42. doi: 10.1007/bf00193708. [PMID: 7768258]
  • W J Remme, D A Kruijssen, D C van Hoogenhuyze, X H Krauss, G L Bartels, C J Storm, P W de Leeuw. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. Journal of cardiovascular pharmacology. 1994 Nov; 24(5):730-9. doi: 10.1097/00005344-199424050-00007. [PMID: 7532750]
  • M Asakura, A Nagakura, S Tarui, R Matsumura. Simultaneous determination of the enantiomers of pimobendan and its main metabolite in rat plasma by high-performance liquid chromatography. Journal of chromatography. 1993 Apr; 614(1):135-41. doi: 10.1016/0378-4347(93)80232-s. [PMID: 8496273]
  • F Hagemeijer. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. European heart journal. 1993 Apr; 14(4):551-66. doi: 10.1093/eurheartj/14.4.551. [PMID: 8472722]
  • P Martin, H Tindall, P Rice, P Jones, G Tregunno, J A Davies, C R Prentice. Effects of pimobendan (UDCG 115) on renal function in healthy volunteers. The Journal of international medical research. 1992 Jun; 20(3):267-72. doi: 10.1177/030006059202000308. [PMID: 1397671]
  • S H Kubo, S Gollub, R Bourge, P Rahko, F Cobb, M Jessup, S Brozena, M Brodsky, P Kirlin, J Shanes. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation. 1992 Mar; 85(3):942-9. doi: 10.1161/01.cir.85.3.942. [PMID: 1537130]
  • H H Erlemeier, W Kupper, W Bleifeld. Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril--a double-blind randomized study. European heart journal. 1991 Aug; 12(8):889-99. doi: 10.1093/eurheartj/12.8.889. [PMID: 1915427]
  • M Przechera, W Roth, V Kühlkamp, T Risler, M Haehl. Pharmacokinetic profile and tolerability of pimobendan in patients with terminal renal insufficiency. European journal of clinical pharmacology. 1991; 40(1):107-11. doi: 10.1007/bf00315148. [PMID: 2060537]
  • F Hagemeijer, H J Brand, W Roth. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. Journal of cardiovascular pharmacology. 1989 Aug; 14(2):302-10. doi: 10.1097/00005344-198908000-00018. [PMID: 2476606]
  • G Baumann, K Ningel, B Permanetter. Cardiovascular profile of UDCG 115 BS-pimobendane and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy. Journal of cardiovascular pharmacology. 1989 May; 13(5):730-8. doi: 10.1097/00005344-198913050-00008. [PMID: 2472521]
  • F Hagemeijer, W Roth, H J Brand. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure. Journal of cardiovascular pharmacology. 1989; 14 Suppl 2(?):S57-64. doi: NULL. [PMID: 2478794]
  • G Baumann, K Ningel, B Permanetter. Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure. Journal of cardiovascular pharmacology. 1989; 14 Suppl 2(?):S23-30. doi: NULL. [PMID: 2478788]
  • H Bitterman, B A Smith, A M Lefer. Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock. Arzneimittel-Forschung. 1988 Oct; 38(10):1389-93. doi: NULL. [PMID: 3196378]
  • M Renard, M Walter, I Liebens, A Dresse, R Bernard. Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. Chest. 1988 Jun; 93(6):1159-64. doi: 10.1378/chest.93.6.1159. [PMID: 3371093]
  • M Walter, I Liebens, H Goethals, M Renard, A Dresse, R Bernard. Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. British journal of clinical pharmacology. 1988 Mar; 25(3):323-9. doi: 10.1111/j.1365-2125.1988.tb03310.x. [PMID: 3282531]
  • P D Verdouw, L Levinsky, D J Duncker, A M Rutteman, P R Saxena. Cardiovascular effects of UD-CG 212 CL, a metabolite of pimobendan, in anaesthetized pigs. European journal of pharmacology. 1987 Jun; 137(2-3):219-26. doi: 10.1016/0014-2999(87)90225-1. [PMID: 2886352]
  • A Eldor, I Vlodavsky, Z Fuks, T H Muller, W G Eisert. Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells. Thrombosis and haemostasis. 1986 Dec; 56(3):333-9. doi: 10.1055/s-0038-1661678. [PMID: 3551181]